Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2022年5月16日 - 7:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022
Commission File Number: 001-40617
Regencell Bioscience Holdings Limited
11/F First Commercial Building
33-35 Leighton Road
Causeway Bay, Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Lock-up of Directors
and Employees
All directors and employees
who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six
months after their stock options become vested; as their stock options are set to vest on July 16, 2022, their shares will remain locked
up until January 16, 2023. A form of the lock-up undertaking is attached hereto as Exhibit 99.1.
Purchases of Ordinary Shares by Chief
Executive Officer
Mr. Yat-Gai Au, the
chairman and chief executive officer of Regencell Bioscience Holdings Limited (the “Company”), has made purchases of ordinary
shares in the Company (“Ordinary Shares”) totaling $5.03 million. Based on his Schedule 13D filings with the U.S. Securities
and Exchange Commission (the “SEC”) between July 27, 2021 and May 16, 2022, Mr. Au used an aggregate of $5.03 million of his
personal funds to purchase Ordinary Shares through open-market purchases. According to the latest filing, following the purchases, Mr.
Au owns a total of 10,539,159 Ordinary Shares, representing 81.0% of total issued and outstanding Ordinary Shares.
The timing, number
and value of Ordinary Shares to be further purchased by Mr. Au, if any, will be determined by Mr. Au in his discretion and will depend
on a variety of factors, including the market price of the Ordinary Shares, general market and economic conditions, available funds and
applicable legal requirements.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 16, 2022
|
Regencell Bioscience Holdings Limited |
|
|
|
|
By: |
/s/ Yat-Gai Au |
|
Name: |
Yat-Gai Au |
|
Title: |
Chief Executive Officer and
Chairman of the Board of Directors |
[Signature Page to Form 6-K]
EXHIBIT INDEX
3
Regencell Bioscience (NASDAQ:RGC)
過去 株価チャート
から 5 2024 まで 6 2024
Regencell Bioscience (NASDAQ:RGC)
過去 株価チャート
から 6 2023 まで 6 2024